Transcript · English → Chinese
Moderna and Merck Cancer Vaccine Trial Results
两家制药公司，莫德纳与默沙东， 对一项临床试验进行了概述，
该试验正在测试 一种新型
癌症疫苗， 与默沙东广泛使用的
癌症治疗药物可瑞达联合使用。
该试验在黑色素瘤患者中进行测试，
而且这是一项
大型试验，他们表示 研究发现其效果
优于单独使用可瑞达， 在
防止疾病复发 或
扩散至身体其他部位方面。
该试验本身针对的是 刚刚通过手术
切除肿瘤的患者。目前， 莫德纳
告诉我们，他们预计有数千名患者
如果获得监管部门批准， 将能从中受益，
而且
获得该批准，他们的目标是，嗯， 在20
27年左右实现。该疫苗 旨在治疗黑色素瘤，呃，
但目前有数十项研究正在探索 其在各类
癌症中的应用，包括肺癌、 胰腺癌、结肠癌等
呃，范围非常广泛。所以这 是科学层面上
首次有迹象表明，呃， 在大规模环境下与其他
治疗手段相比， 它是有效的。
这一消息对莫德纳公司来说 意义极其重大。
我们的读者可能熟知莫德纳是 一款高效
新冠疫苗的制造商，呃，他们的， 你知道，他们的
财富因该疫苗而暴涨，你知道， 在疫情期间及紧随其后的
时期。呃，但自那以后， 该疫苗的使用已经，已经
放缓，而研发一款 癌症疫苗的构想，
基于其mRNA技术，呃， 吸引了大量的
关注。今天的新闻表明 有更多证据让人
相信这一希望能够成真， 并且会形成一个庞大的市场。
这些结果，呃， 对默克公司而言也是实实在在的利 好。
呃，你知道，他们 因可瑞达（Keytruda）而闻名，呃，
面向癌症患者。
他们正在测试这种疫苗方案， 这、在多项不同的
试验中。呃， 所以这开辟了新的可能性，针对
针对默克
以及，你知道，以及其自身的疗法。
呃， 这意义重大，因为相关专利
针对那个，
针对可瑞达， 预计将在
本年代内或晚些时候到期，
而且，你知道，而且、而且这，你知道， 正在为他们打开市场。
End of transcript · 389 words · machine translated
Original transcript (English)
Two drug makers, uh, Moderna and Merck, gave an overview, uh, of a clinical trial that was testing, um, a new cancer vaccine, uh, together with a widely used cancer treatment from Merck called Keytruda. Uh, it was testing it in melanoma patients
and, uh, it was a large trial, uh, and they said that what they found is that it works better than just Keytruda by itself, uh, when it comes to preventing the disease from returning, uh, or from spreading to other parts of the body.
The trial itself was looking at patients who had just had their tumors removed surgically. At the moment, uh, Moderna has told us that they expect that there are thousands of patients, uh, who could benefit from this if they receive regulatory approval, uh, and that
that approval, their aim is to get it, um, sometime in twenty twenty-seven. This is designed to treat melanoma, uh, but there are dozens of studies looking at this in all kinds of cancers, in lung cancer, in pancreatic cancer, colon cancer, uh, a, a wide array. So this is the first sign
scientifically, uh, that in a large setting compared to other kinds of treatment, that this works. The news is extremely significant for Moderna. Our readers may know Moderna as the maker of a very effective COVID-19 vaccine, uh, and their, you know, their
fortunes surged on that vaccine, you know, during and immediately after the pandemic. Uh, but since then, use of the vaccine has, has slowed, and the idea of a, of a cancer vaccine based on its mRNA technology, uh, has attracted a lot of interest. The news today signals that there is more evidence to
think that that hope will materialize, and it will become a big marketplace. The results are also, uh, a real positive for Merck. Uh, you know, they are very well known for Keytruda, uh, for cancer patients. They are testing this vaccine approach, this, i-- in a number of different
trials. Uh, so it opens up a new possibility for, for Merck and its, you know, and its own therapy. Uh, and that is significant because the patent on that,
on Keytruda, is expected to expire within or later in this decade and, you know, and, and this is, you know, opening up their market for them.
